ArticleCancers2019

Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori.

Yoshimasa Saito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.